• Vaccine Name: Influenza A (H1N1) 2009 Monovalent Vaccine by Novartis
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Product Name: Influenza A (H1N1) 2009 Monovalent Vaccine
• Manufacturer: Novartis Vaccines and Diagnostics Limited
• Vaccine Ontology ID: VO_0000081
• Type: Inactivated or "killed" vaccine
• Status: Licensed
• Location Licensed: USA
• Host Species for Licensed Use: Human
• Antigen: pandemic (H1N1) 2009 influenza virus
• Preparation: Influenza A (H1N1) 2009 Monovalent Vaccine is prepared from influenza virus propagated in the allantoic fluid of embryonated chicken eggs which have been inoculated with a influenza virus suspension containing neomycin and polymyxin. The virus is then harvested by centrifugation and filtration and then inactivated with betapropiolactone. The surface antigens, hemagglutinin and neuraminidase are obtained from the virus particle via further centrifugation in the presence of nonylphenol ethoxylate, a process which removes most of the internal proteins. The nonylphenol ethoxylate is removed from the surface antigen preparation (FDA: H1N1 Novartis Vaccine).
• Immunization Route: Intramuscular injection (i.m.)
• Virulence: Inactivated
• Storage: Store between 2º and 8ºC (36º and 46ºF)
• Approved Age for Licensed Use: Ages 4 and older
• Contraindication: Hypersensitivity to eggs or chicken protein, neomycin, or polymyxin, or life-threatening reaction to previous influenza vaccination.

Human Response

• Side Effects: The most common side affects are mild hypersensitivity reactions such as rash, local reactions at the injection site and influenza like symptoms (FDA: H1N1 Novartis Vaccine).